Rare Hereditary Cancers

Advances in Genetic Testing for Hereditary Cancer Syndromes.

Rare Hereditary Cancers

Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, April 2016

27075345

978-3-31-929996-9, 978-3-31-929998-3

Ellen Thomas, Shehla Mohammed

Gabriella Pichert, Chris Jacobs

The ability to identify genetic mutations causing an increased risk of cancer represents the first widespread example of personalised medicine, in which genetic information is used to inform patients of their cancer risks and direct an appropriate strategy to minimise those risks. Increasingly, an understanding of the genetic basis of many cancers also facilitates selection of the most effective therapeutic options. The technology underlying genetic testing has been revolutionised in the years since the completion of the Human Genome Project in 2001. This has advanced knowledge of the genetic factors underlying familial cancer risk, and has also improved genetic testing capacity allowing a larger number of patients to be tested for a constitutional cancer predisposition. To use these tests safely and effectively, they must be assessed for their ability to provide accurate and useful results, and be requested and interpreted by health professionals with an understanding of their strengths and limitations. Genetic testing is increasing in its scope and ambition with each year that passes, requiring a greater proportion of the healthcare workforce to acquire a working knowledge of genetics and genetic testing to manage their patients safely and sensitively.